Exhibits several functions, including A1 adenosine receptor binding activity; G protein-coupled purinergic nucleotide receptor activity; and adenyl ribonucleotide binding activity. Involved in several processes, including positive regulation of cellular metabolic process; purinergic nucleotide receptor signaling pathway; and regulation of secretion by cell. Localizes to several cellular components, including basolateral plasma membrane; postsynaptic density; and synaptic membrane. Colocalizes with mitochondrion. Used to study impotence. Orthologous to human P2RY1 (purinergic receptor P2Y1); INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
bisindolylmaleimide I inhibits the reaction [P2RY1 protein affects the reaction [Nucleotides results in increased phosphorylation of and results in increased activity of MAPK1 protein]], bisindolylmaleimide I inhibits the reaction [P2RY1 protein affects the reaction [Nucleotides results in increased phosphorylation of and results in increased activity of MAPK3 protein]]
[N(6)-methyl-2'-deoxyadenosine 3', 5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium]
[bisphenol A co-treated with Estradiol] results in decreased expression of P2RY1 mRNA, [bisphenol A co-treated with Testosterone] results in decreased expression of P2RY1 mRNA
1-Butanol inhibits the reaction [P2RY1 protein affects the reaction [Nucleotides results in increased phosphorylation of and results in increased activity of MAPK1 protein]], 1-Butanol inhibits the reaction [P2RY1 protein affects the reaction [Nucleotides results in increased phosphorylation of and results in increased activity of MAPK3 protein]]
[N(6)-methyl-2'-deoxyadenosine 3', 5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium]
[N(6)-methyl-2'-deoxyadenosine 3', 5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P2RY1 mRNA
P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
rottlerin inhibits the reaction [P2RY1 protein affects the reaction [Nucleotides results in increased phosphorylation of and results in increased activity of MAPK1 protein]], rottlerin inhibits the reaction [P2RY1 protein affects the reaction [Nucleotides results in increased phosphorylation of and results in increased activity of MAPK3 protein]]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P2RY1 mRNA
Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P2RY1 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
